ALAS1
5-aminolevulinate synthase, non-specific, mitochondrial
As of the edition of 20 October 2026, ALAS1 (5-aminolevulinate synthase, non-specific, mitochondrial, UniProt P13196) has 2 drugs tested at it and 1 company on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P13196
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Digestive system; Inherited and neonatal; Nutrition and metabolism; Skin and connective tissue
- Registered trials of its drugs
- 4
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Givosiran | Marketed | Phase 3 | none listed |
| Givosiran sodium | Marketed | No phase stated | Ends 2034 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Alnylam Pharmaceuticals | Route B |
The other 0 companies at ALAS1
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at ALAS1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.